2026 ICD-10-CM Diagnosis Code M36.0Dermato(poly)myositis in neoplastic disease

ICD-10-CM CodesM00–M99M30-M36M36

ICD-10-CM M36.0
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

M36.0 is a billable ICD-10-CM diagnosis code for dermato(poly)myositis in neoplastic disease. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 545 through 547. The code is a manifestation code that cannot be reported as the principal diagnosis. Coders also document this condition as dermatomyositis with malignant disease. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Conditions due to neoplasm or the treatment of neoplasm and Systemic lupus erythematosus and connective tissue disorders.

Code Identity

ICD-10-CM Code
M36.0
Billable Status
Yes — Valid for Submission
Code Describes
Dermato(poly)myositis in neoplastic disease
Short Description
Dermato(poly)myositis in neoplastic disease
Same as the full description in the CMS dataset.
Parent Code
Systemic disorders of connective tissue in diseases classified elsewhere

Code Classification

ChapterM00–M99Diseases of the musculoskeletal system and connective tissue
SectionM30-M36Systemic connective tissue disorders
CategoryM36Systemic disorders of connective tissue in diseases classified elsewhere
This CodeM36.0Dermato(poly)myositis in neoplastic disease

Code EditsBilling

Medicare Code Editor checks that affect claim validity for M36.0.

Manifestation codes describe the manifestation of an underlying disease, not the disease itself, and therefore should not be used as a principal diagnosis.

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Dermatomyositis with malignant disease
  • Juvenile polymyositis
  • Juvenile polymyositis due to paraneoplastic syndrome
  • Myopathy due to paraneoplastic syndrome
  • Polymyositis

Tabular List NotesGuidance

Coding notes and annotation back-references applicable to this code.

Code First

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR NEO074
Conditions due to neoplasm or the treatment of neoplasm
Default principal diagnosis: inpatient No · outpatient No
CCSR MUS024
Systemic lupus erythematosus and connective tissue disorders
Default principal diagnosis: inpatient No · outpatient No

Clinical InformationClinical

  • Dermatomyositis

    a subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. the illness occurs with approximately equal frequency in children and adults. the skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. the disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. the childhood form of this disease tends to evolve into a systemic vasculitis. dermatomyositis may occur in association with malignant neoplasms. (from adams et al., principles of neurology, 6th ed, pp1405-6)
  • Polymyositis

    diseases characterized by inflammation involving multiple muscles. this may occur as an acute or chronic condition associated with medication toxicity (drug toxicity); connective tissue diseases; infections; malignant neoplasms; and other disorders. the term polymyositis is frequently used to refer to a specific clinical entity characterized by subacute or slowly progressing symmetrical weakness primarily affecting the proximal limb and trunk muscles. the illness may occur at any age, but is most frequent in the fourth to sixth decade of life. weakness of pharyngeal and laryngeal muscles, interstitial lung disease, and inflammation of the myocardium may also occur. muscle biopsy reveals widespread destruction of segments of muscle fibers and an inflammatory cellular response. (adams et al., principles of neurology, 6th ed, pp1404-9)

Patient EducationClinical

Myositis

Myositis means inflammation of the muscles that you use to move your body. An injury, infection, or autoimmune disease can cause it. Two specific kinds are polymyositis and dermatomyositis. Polymyositis causes muscle weakness, usually in the muscles closest to the trunk of your body.

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert M36.0 to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
710.3 Dermatomyositis
Approximate The match is approximate rather than exact.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About M36.0Overview

Is M36.0 a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report dermato(poly)myositis in neoplastic disease on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What MS-DRG does M36.0 group to?

On inpatient claims, dermato(poly)myositis in neoplastic disease maps to MS-DRG 545, 546, 547, with relative weights from 0.8362 to 2.4817 depending on complications. Higher weights mean higher Medicare reimbursement.

Can M36.0 be a principal diagnosis?

No. This is a manifestation code: dermato(poly)myositis in neoplastic disease describes the manifestation of an underlying disease rather than the disease itself, so the underlying condition is sequenced first.

What is the ICD-9 equivalent of M36.0?

Under the General Equivalence Mappings, dermato(poly)myositis in neoplastic disease converts to ICD-9-CM 710.3 (dermatomyositis). The mapping is approximate, so confirm the match fits the documentation.

Footnotes

[1] Chronic - a chronic condition code indicates a condition lasting 12 months or longer and its effect on the patient based on one or both of the following criteria:

  • The condition results in the need for ongoing intervention with medical products,treatment, services, and special equipment
  • The condition places limitations on self-care, independent living, and social interactions.